• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Published Clinical Study Shows Zynex's NeuroMove Stroke Recovery Systems As Enabling Patients to Advance to Physical Therapy

Posted on: Wednesday, 1 March 2006, 09:01 CST

Zynex Medical Holdings, Inc. (OTCBB: ZYNX), a provider of pain management systems and electrotherapy products for medical patients with functional disability, today announced that stroke victims who took part in an independent published clinical study conducted by researchers at the University of Cincinnati College of Medicine were able to participate in a specialized physical therapy program after being treated with the Company's NeuroMove(TM) Stroke Recovery System.

The study was conducted by Stephen J. Page, Ph.D., and Peter Levine, BA, PTA, both affiliated with the University of Cincinnati's Department of Physical Medicine and Rehabilitation and the Drake Rehabilitation Center. The results of the study were published in the January 2006 edition of the Archives of Physical Medicine and Rehabilitation, the most prominent journal in its field. It is published by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.

"The study found that after using the NeuroMove for a short period of time, patients who were unable to use their wrist or fingers at all, regained enough movement to progress to the next level of therapy," stated Zynex President and Chief Executive Officer Thomas Sandgaard. "The NeuroMove System provided the patients the ability to undergo Modified Constraint Induced Therapy (mCIMT), a form of physical therapy, where they continued to make progress in their recovery."

"This study is one of the first to show that a therapy program can address movement in stroke patients who initially had little or no hand motor control, and it is among the first to effectively combine two singularly efficacious regimes such as the NeuroMove and modified constraint therapy," Dr. Page said.

The NeuroMove(TM) System increases the functionality of many stroke victims by teaching the healthy parts of the brain to compensate for damaged areas. The NeuroMove(TM), which is significantly more sensitive than most diagnostic equipment, monitors muscle activity and selects signals from the brain indicating that the patient is attempting to move a certain muscle. It then introduces the actual movement through electrical stimulation. Eventually the connection between the brain and muscle can often be reestablished. The NeuroMove(TM) (www.neuromove.com) also can be used to treat spinal cord injuries.

About Zynex

Zynex Medical Holdings, Inc., (www.zynexmed.com), a leading provider of therapeutic devices for patients with functional disability through the creation, distribution, and marketing of electrotherapy devices since 1996, strives to uphold its mission to improve the quality of life of patients suffering from debilitating pain or illness by providing innovative technology. Utilizing a unique combination of electromyographic (EMG) technology combined with a system of instruction and reinforcement, including electrical muscle stimulation (EMS), Zynex offers new treatment options to post-stroke and spinal injury patients.

Safe Harbor Provision

Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the Company's ability to meet terms and conditions required to obtain project financing, risks and delays associated with product development, risk of market acceptance of new products, technology or product obsolescence, competitive risks, reliance on development partners and additional capital needs.

Source: Business Wire

More News in this Category